Navigation Links
Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Date:5/3/2012

ure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to increase exposure of dabigatran compared to either factor alone.

  • For patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA.
  • For patients with severe renal impairment (CrCl 15-30 mL/min), avoid concomitant use of PRADAXA and P-gp inhibitors.

ADVERSE REACTIONS

In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal (GI) events. PRADAXA 150 mg resulted in a higher rate of major GI bleeds and any GI bleeds compared to warfarin. In patients ≥75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions. These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer). Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

OTHER MEASURES EVALUATED

The risk of myocardial infarction was numerically greater in patients who received PRADAXA 150 mg than in those who received warfarin.

For full PRADAXA prescribing information, please visit www.pradaxa.com or contact Boehringer Ingelheim's Drug Information Unit at 1-800-542-6257.

About the Boehringer Ingelheim Cares Foundation Patient Assistance Programs

For more than 125 years, Boehringer Ingelheim has been focused on improving the lives of patients
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013   National Community Pharmacists Association ... RPh, MBA issued the following statement today regarding a ... Part D "preferred pharmacy" drug plans , which ... plan,s lowest advertised co-payments: (Logo:  http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ... and MedPAC , 16 U.S. Senators ...
(Date:5/20/2013)... , May 20, 2013  TRACE International today ... 2012 , finding that prosecutions against individuals and government ... last year. The GER 2012 is the ... international anti-bribery enforcement trends. "Although the number ... of bribery laws remained a priority," said ...
(Date:5/20/2013)... , May 20, 2013   Life Technologies ... that its Applied Biosystems™ 3500 Dx and 3500xL Dx ... for Protection against Health Risks in Mexico ... major extension of Life Technologies, capabilities to serve the ... with Sanger -based solutions.  ...
Breaking Medicine Technology:Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3
... both ethical and practical grounds, direct programming is ... pluripotent stem,cells.", WASHINGTON, Nov. 20 Two ... Cell unveil a proven way to,generate patient-matched human ... use of human embryos or human or animal ...
... of circulating cancer cells in 40,billion blood cells, ... WARREN, N.J., Nov. 20 Veridex, LLC ... (FDA) has granted an,expanded clearance for the CellSearch(TM) ... monitoring of metastatic colorectal cancer. CellSearch is currently,approved ...
Cached Medicine Technology:Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 2Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 3FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 2FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 3FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 4
(Date:5/20/2013)... McLean, VA (PRWEB) May 20, 2013 ... (EDRA) Annual Conference will feature dozens of continuing ... approved by the American Institute of Architects Continuing ... System (LA CES), and the Interior Design Continuing ... May 29 – June 1, 2013 at the ...
(Date:5/20/2013)... Co-founder of Atlanta SEO company ... at the 5th International INVEST Domaining & Internet Marketing ... company representatives and independent individuals from around the world ... investments. , The 2013 conference will take place at ... May 20 to 21. A networking city tour day ...
(Date:5/20/2013)... May 20, 2013 The judge overseeing ... lawsuits has called specifically for female lawyers to be ... The Rottenstein Law Group LLP acknowledges the judge’s request, ... lawsuits by providing information on Mirena side effects ... Seibel called for the addition of some female lawyers ...
(Date:5/20/2013)... Branch at Galveston researchers have been awarded a five-year, ... Disorders and Stroke to apply the techniques of gene ... is, pain that arises from a malfunction in the ... reality for millions of Americans, manifesting itself in a ... might feel intense discomfort in response to a light ...
(Date:5/20/2013)... 20, 2013 Dorland Health, a ... the fourth annual Case In Point Platinum Awards, ... to ensuring the system is patient- and family-centric, ... innovative and creative work across the healthcare system ... safe transitions of care through effective care coordination ...
Breaking Medicine News(10 mins):Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2Health News:Pain, pain, go away 2Health News:Pain, pain, go away 3Health News:Dorland Health Announces the 2013 Case In Point Platinum Awards Winners 2
... ... Announced by ERISAclaim.com for Healthcare Providers to Appeal Claim Denials and Delays, to Comply with ... Plans And Healthcare Providers. , ... Hanover Park, IL (PRWEB) June 28, 2010 -- ERISAclaim.com announced the nation,s first new ...
... ... that provides a comprehensive view of California public policy and legislative issues. Available ... one site. , ... 28, 2010 -- The ‘LegisWeb Eye’ launches on July 1st, bringing a new legislative information ...
... lowered the obesity rate in students at highest risk for ... in sixth grade, an NIH-funded study has found. However, ... schools in the study,s primary outcomethe prevalence of overweight and ... schools by the end of the three-year study. The ...
... ... Tarot Professionals Ltd establishes Tarosophy® Tarot Houses worldwide ... being prepared to warn Tarot readers by highlighting certification scams, bad ... field. Tarot Professionals Ltd continues to introduce innovative Tarot courses – ...
... People with type 1 diabetes who have early and ... in the urine, are six times more likely to die ... of Pittsburgh Graduate School of Public Health. Their study, being ... Association, also found that when kidneys remained normal over time, ...
... , ... Henninger Media Services, the largest production/post-production company in the Mid-Atlantic region, acquires premiere ... Clients include National Geographic Films, Discovery Networks and various documentary filmmakers. ... (PRWEB) ...
Cached Medicine News:Health News:New Health Reform Law Claim Denial Appeal Book Announced for Healthcare Providers to Comply with New PPACA Deadline - 09/23/2010 2Health News:New Health Reform Law Claim Denial Appeal Book Announced for Healthcare Providers to Comply with New PPACA Deadline - 09/23/2010 3Health News:New Health Reform Law Claim Denial Appeal Book Announced for Healthcare Providers to Comply with New PPACA Deadline - 09/23/2010 4Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 2Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 3Health News:Intervention lowered obesity rate in youth at high diabetes risk, HEALTHY study finds 2Health News:Intervention lowered obesity rate in youth at high diabetes risk, HEALTHY study finds 3Health News:Tarosophy Deals A Fair Hand for All Tarot Seekers 2Health News:Tarosophy Deals A Fair Hand for All Tarot Seekers 3Health News:Tarosophy Deals A Fair Hand for All Tarot Seekers 4Health News:Henninger Media Services Now Offers Hollywood-Quality Blu-ray Products 2Health News:Henninger Media Services Now Offers Hollywood-Quality Blu-ray Products 3
The ultimate combination of comfort, convenience and affordability, recommended for daily wear, also approved for extended wear (1-7 days)....
Acuvue2 is designed to be worn as a two-week daily wear lens (which means you take the lenses out each night). It can also be worn as a one-week extended wear lens (which means you can sleep in them)...
... water content spherical soft lens manufactured using ... molding technology, and designed for use in ... a daily wear or extended wear basis. ... transmission, while an increased mid-peripheral thickness allows ...
Hertel exophthalmometer...
Medicine Products: